



## Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe

**OSLO, NORWAY – 7 November 2022:** Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for the distribution of the GA-map® Dysbiosis Test in Europe.

GA and the diagnostic partner are now in the launch phase for selected European markets and expect this to fuel revenues from 2023.

There is increasing demand for gut microbiome assessments in the private healthcare service, medical clinics, and academic research globally. The GA-map® product offering will target labs performing services to both clinical diagnostic customers and clinical research customers. The GA-map® platform offers a fast turnaround lab testing service for microbiome analysis with an integrated software algorithm for immediate result presentation.

***Ronny Hermansen, CEO, Genetic Analysis, comments:***

*“GA is thrilled to have signed up with this important partner for the European market and we are convinced that the GA-map® will be a significant add-on to their already strong product portfolio”.*

**For further information, please contact:**

Ronny Hermansen, CEO

E-mail: [rh@genetic-analysis.com](mailto:rh@genetic-analysis.com)

Eilert Aamodt, Chief Financial Officer

E-mail: [ea@genetic-analysis.com](mailto:ea@genetic-analysis.com)

**About Genetic Analysis**

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting-edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to helping unlock and restore the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information: [www.genetic-analysis.com](http://www.genetic-analysis.com)